Vericel Announces Change to a Virtual Meeting Format For 2020 Annual Meeting of Shareholders
April 10 2020 - 9:00AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced that as a result of the COVID-19 pandemic, to support the
health and well-being of our employees and shareholders, and to
comply with state stay-at-home orders, including the Commonwealth
of Massachusetts’ Executive Order prohibiting gatherings of more
than ten people, its Board of Directors has approved a change in
location of its 2020 Annual Meeting of Shareholders to a
virtual-only shareholders meeting instead of an in-person meeting.
As previously announced, the Annual Meeting will be held on
Wednesday, April 29, 2020 at 9:00 a.m. local time (Eastern Daylight
Time). Shareholders will not be able to attend the Annual Meeting
in person.
As described in the proxy materials for the
Annual Meeting previously distributed, shareholders are entitled to
participate in the Annual Meeting if they were a shareholder of
record at the close of business on March 5, 2020.
To be admitted to the Annual Meeting at
www.virtualshareholdermeeting.com/VCEL2020 shareholders must enter
the control number found on the proxy card, voting instruction form
or notice they previously received. Shareholders may vote during
the Annual Meeting by following the instructions available on the
meeting website during the meeting.
Whether or not they plan to attend the Annual
Meeting, shareholders are urged to vote and submit their proxy in
advance of the meeting by one of the methods described in the proxy
materials for the Annual Meeting. The proxy card included with the
proxy materials previously distributed will not be updated to
reflect the change in location and format, but should continue to
be used by shareholders to vote shares in connection with the
Annual Meeting.
About Vericel
CorporationVericel is a leader in advanced therapies for
the sports medicine and severe burn care markets. The company
markets two cell therapy products in the United States. MACI®
(autologous cultured chondrocytes on porcine collagen membrane) is
an autologous cellularized scaffold product indicated for the
repair of symptomatic, single or multiple full-thickness cartilage
defects of the knee with or without bone involvement in adults.
Epicel® (cultured epidermal autografts) is a permanent skin
replacement for the treatment of patients with deep dermal or
full-thickness burns greater than or equal to 30% of total body
surface area. The company also holds an exclusive license for North
American commercial rights to NexoBrid®, a registration-stage
biological orphan product for debridement of severe thermal burns.
For more information, please visit the company’s website at
www.vcel.com.
Epicel® and MACI® are registered trademarks of
Vericel Corporation. NexoBrid® is a registered trademark of
MediWound Ltd. and is used under license to Vericel Corporation. ©
2020 Vericel Corporation. All rights reserved.
Global Media Contacts:David SchullRusso
Partners LLCDavid.schull@russopartnersllc.com+1 212-845-4271
(office)+1 858-717-2310 (mobile)
Investor Contacts:Lee SternSolebury
Troutlstern@troutgroup.com+1 (646) 378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Sep 2023 to Sep 2024